Suitable candidates include patients with small tumor size (HCC ≤ 50 mm), low T stage of tumor, prehepatectomy PIVKA-II level of <200 mg/dl, low AFP level at detection of PR (<200 ng/dl), and long interval between hepatectomy and PR (>6 months). This evidence concerns the gene AFP and hepatocellular carcinoma.